Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCO-120 in HR+/HER2- Advanced Breast Cancer
NCT04942054Phase 1Terminated
- Sponsor
- Sun Pharma
- Start
- May 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of bexirestrant in breast cancer (3 arms), sponsored by Sun Pharma. Primary endpoints: Incidence of Dose Limiting Toxicities and Incidence and Severity of Adverse Events. Started May 2022; status: terminated.
02
Drugs
bexirestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04942054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04942054.